Lovaltech is dedicated to the development of nasal vaccines that trigger the mucosal compartment of the immune system and immediately block the transmission of the infectious agent in addition to activating the classical humoral and cellular immune system. The company was launched in 2022 as a spin-off from the University of Tours (France) and has been awarded the France 2030 Deeptech label in recognition of its excellence in pioneering a radically new approach to vaccination.